Long Shortz with Lumos: US$317M Deal Sets New Benchmark for ASX Diagnostics

Atomo Diagnostics investors are excited about their fair share from Lumos Diagnostics' A$487m distribution deal

Yesterday was a great day for Atomo Diagnostics investors as shares climbed up to 56% higher and closed 25% above the previous day’s closing price. The catalyst was an A$487m deal signed by Lumos Diagnostics, one of Atomo’s key business partners and investors believe the company will carve out some of this for itself. How…

Lumos Diagnostics surges 140% on major US contract deal

Lumos Diagnostics (ASX:LDX) has surged +140% to sell at 7cps in Wednesday’s lunchtime trade after inking a $420 million deal for use of its fingerprick blood test, FebriDX, to determine if an infection is bacterial or not. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. While a far cry from the infamous Theranos product that claimed to diagn…

Long Shortz with Lumos: US$317M deal sets new benchmark for ASX diagnostics

Tylah Tully chats with Lumos Diagnostics (ASX:LDX) CEO Doug Ward after the company inked one of the largest distribution deals ever for an ASX-listed point-of-care diagnostics company. The exclusive US$317 million agreement with PHASE Scientific is a landmark for Lumos as it progresses FebriDx through the FDA CLIA waiver process, oping doors to a further billion-dollar US market. Ward also shares insight into BARDA’s $8.3 million funding, the im…